NPS reports positive results from Phase III study of Gattex
Results showed that 68% of the 25 patients who had received low-dose Gattex therapy and continued on low-dose Gattex, and 52% of the 27 patients who had received
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).